Half of a trial on the effectiveness of Kevzara against COVID-19 was halted while the other portion will continue, researchers said Monday.
The trial on Kevzara, also known as sarilumab, started last month in patients hospitalized with COVID-19, the disease caused by the CCP (Chinese Communist Party) virus, a novel coronavirus that emerged from mainland China last year.
